April 25, 2016
Janssen Pharmaceutical said on April 22 that it has filed its TNFα monoclonal antibody Simponi (golimumab) in Japan as an induction therapy and maintenance therapy for moderate-to-severe ulcerative colitis (UC). The latest filing is based on global PIII study data,...read more